THCbiz

Advertisement

Thu12132018

      Cannabis Industry B2B Directory: Featured Businesses
Back You are here: Home Features Spotlight EXCLUSIVE: First look inside Cannabics Pharmaceuticals Inc.

EXCLUSIVE: First look inside Cannabics Pharmaceuticals Inc.


first look into Cannabics Pharmaceuticals inc.

THCbiz.com exclusive first look inside Cannabics Inc. R&D laboratories in Israel, MMJ product lineup, and the people behind the company.

Cannabics Pharmaceuticals Inc. is a biotech company founded in 2011 by a leading group of entrepreneurs and researchers from the fields of Molecular biology, cancer therapy and pharmacology. Setting forth a new approach in the science of cannabis based therapy, the company's main interests is to be in the treatment of malignancies, autoimmune diseases, pain, brain disorders and attention.

Cannabics products are designed to address the most important unmet needs in today’s medical cannabis use, which are standardization, reproducibility and ease of administration. The company produces standardized cannabis pills, which contain the pure extract of cannabis Sativa and Indica hybrid plants. By using different strains for diverse indications, the company can provide exact combinations of active cannabinoids that address the exact needs of various patient populations.

Cannabics vision is to embrace the therapeutic nature of cannabis.

The company produces standardized cannabis pills, which contain pure extract of cannabis Sativa and Indica hybrid plants.

cannabics labs

Scientific Research

The scientific research in Cannabics begins with a dedicated and experienced team of agronomists who are constantly working on breeding and developing unique strains of cannabis plants, especially tailored and designed to enhance the therapeutic properties they posses. The company has developed a unique and valuable knowledge base regarding the medical capabilities of each strain, and the various indications that are most suitable for it. By carefully breeding their strains, they constantly develop new medical cannabis plants tailored to the exact needs of various patient populations.

In addition, the team of pharmacists in these working laboratories are constantly developing new formulations of medical cannabis that will suit the exact needs of their patients. By using only food-grade organic components, they have developed a line of easy-to-administer and standardized products that revolutionize the use of medical cannabis. Thus, by combining comprehensive knowledge of the medical qualities of different strains of cannabis and unique natural formulations, exact healing solutions and the natural therapeutic power of cannabis can be provided to patients of multiple illnesses. 

Cannabics laboratories have developed a wide range of solutions for standardized, reproducible and easy administration of medical cannabis products which avoid the common unhealthy and unstandardized method of smoking the raw flowers of the plant, in order to achieve the desired therapeutic effects of the active cannabinoids that are contained within it.

As it's nearly impossible to perform clinical research on marijuana in the United States since the Controlled Substances Act has upheld marijuana as one of the most "dangerous drugs" available, Cannabics' research and development laboratories are located in Israel. Marijuana is illegal in Israel but medical use has been permitted since the early 1990s for cancer patients and those with pain-related illnesses such as Parkinson's, multiple sclerosis, and even post-traumatic stress disorder. Patients can smoke the drug, ingest it in liquid form, or apply it to the skin as a balm. Noted by a story in USA Today, the medical cannabis industry is expanding fueled by Israel's strong research sector in medicine and technology - and notably, by government encouragement. The story also brings into light that unlike in the United States and much of Europe, the issue inspires almost no controversy among the government and the country's leadership.

cannabics nursery

Behind the Company

Dr. Eyal Ballan, director of R&D for the Cannabics, told THCbiz.com, "Cannabics vision is to embrace the therapeutic nature of cannabis. From ways of administration to nanotechnology, cannabics engages a multidisciplinary research and produces advanced and highly specific medicines."  Ballan has a rich background in anticancer drug development and in neuro-pharmacology and holds a B.Sc. in biology, M.Sc. in Neuro-Biochemistry and a Ph.D. in brain and behavior. 

Dr. Zohar Koren, co-founder of the company, has an extensive background in the pharmaceutical field development, regulations, and preclinical and clinical research. Dr. Koren has a B.Sc. in Mathematics and Physics, M.Sc. and Ph.D. in Computational Biology.

Cannabics MMJ Products

MMJ Product Lineup

Cannabics provides 25 mg of slow-release capsules to medical cannabis patients that obtain a doctor's recommendation. All products are purely natural with no chemical substances added. The company states that they have developed a patented and unique method of extraction in order to achieve a pure extract of the active cannabinoids from organic and unique strains of cannabis. The excipients that are used in their formulations are all common food-grade materials, with no artificial additives. The line of products include:

  • Cannabics SR – A patented sustained release cannabinoid pill
  • Cannabics IN – Capsules for dry powder inhalers.
  • Cannabics VP – Condensed pills for use in standard Vaporizers.

Cannabics was established in 2011 in Israel and also recorded in 2012 at the state of Delaware to facilitate the company's planned issuance. In 2012, the company established their research division and in the beginning of 2013 started enrollment of patients for a series of clinical studies with their products in diverse indications such as Alzheimer’s, Cancer, Multiple sclerosis, Chronic pain and PTSD combat.

As of today Cannabics products are circulating though 5 hospitals in Israel. The numbers of patients authorized to use marijuana is Israel is still far lower than those in the U.S. states where it is legal. Colorado, for example, has over 100,000 registered patients in a population of 5 million, compared the 10,000 in Israel, a country of 8 million people. 

In mid-2013 Cannabics' plans to begin extensive research on integrated cannabinoid anticancer medicines. The company is also implementing steps in becoming publicly traded in the United States and Europe in the very near future. For more information, questions or investing inquiries please visit www.cannabics.com.


Advertisement
Advertisement